Lates News

Every AI Express News, Huaxi Securities issued a research report on November 1, giving Yifan Medicine (002019.SZ) a "buy" rating. The main reasons for the rating include: 1) improvement in income structure, slight increase in gross profit margin, and a decrease in expense ratio; 2) improvement in sales situation, continued increase in innovative drugs; 3) extension of the patent term of Yilishu, IL-15 double fusion protein IND. (China Economic News)